Celldex Remains A Premier Immunotherapy Player To Watch Going Into 2015, Says Roth Capital
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) with a $40 price target, following the company’s third-quarter results, posting EPS of ($0.31) and revenue of $1.1 million.
Pantginis noted, “With multiple data milestones on the horizon and the initiation of several highly-anticipated combination studies expected in 4Q, we believe CLDX remains a premier immunotherapy player to watch going into 2015.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -6.6% and a 42.9% success rate. Pantginis has a 1.3% average return when recommending CLDX, and is ranked #3308 out of 3362 analysts.